"Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals. I am proud of the relentless passion and Cresco-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our worldwide R&D team is working tirelessly to advance the Phase 3 trials of our COVID-19 vaccine and to uphold the highest standards of transparency, safety and efficacy; while other dedicated teams provide ongoing support to hospitals and patients as they return to sites of care, and ensure patients and consumers have the medicines and products they need. This resilient mindset, combined with our strategic capabilities and execution excellence, increase our optimism for continued recovery in 2021 and strong momentum entering into 2022."

Worldwide Consumer Health Sales
Consumer Health worldwide reported sales increased 1.3% or 3.0% operationally.1 Primary operational drivers:

Worldwide Pharmaceutical Sales
Pharmaceutical worldwide reported sales increased 5.0% or 4.4% operationally.1 Primary operational drivers:

Worldwide Medical Devices Sales
Medical Devices worldwide reported sales decreased (3.6)% or (3.3)% operationally. Primary offsets to decline:

Note: values may have been rounded


1The non-GAAP financial results and the reconciliation of those results to the most comparable GAAP financial measures are provided in the investor section of the Earnings Release. The non-GAAP financial measure excludes the impact of non-recurring items.

1The non-GAAP measure excludes the impact of non-recurring items.

1The non-GAAP measure excludes the impact of non-recurring items. The documentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to place undue reliance on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, readers are directed to the "Risk Factors" section of our Johnson & Johnson earnings release issued on October 13, 2021, as well as the most recently filed Johnson & Johnson annual or quarterly report(s) with the U.S. Securities and Exchange Commission ("SEC"). J&J does not undertake to update any forward-looking statement as a result of new information or future events or developments.